tiprankstipranks
Advertisement
Advertisement

CPRX Stock Latest News

Catalyst Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
The FlyCatalyst Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
7d ago
CPRX
Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 79c, consensus 64c
PremiumThe Fly
Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 79c, consensus 64c
24d ago
CPRX
Catalyst Pharmaceuticals not providing forward-looking guidance
PremiumThe Fly
Catalyst Pharmaceuticals not providing forward-looking guidance
24d ago
CPRX
Catalyst Pharma Reports Higher Revenue, Suspends Earnings Guidance
PremiumCompany Announcements
Catalyst Pharma Reports Higher Revenue, Suspends Earnings Guidance
24d ago
8K
CPRX
CPRX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
CPRX Upcoming Earnings Report: What to Expect?
24d ago
CPRX
Catalyst Pharmaceuticals downgraded to Neutral from Buy at Citi
PremiumThe FlyCatalyst Pharmaceuticals downgraded to Neutral from Buy at Citi
27d ago
CPRX
Catalyst Pharmaceuticals downgraded to Neutral from Outperform at Baird
Premium
The Fly
Catalyst Pharmaceuticals downgraded to Neutral from Outperform at Baird
28d ago
CPRX
Catalyst Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
Premium
The Fly
Catalyst Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
28d ago
CPRX
Catalyst Pharma Settles Firdapse Patent Litigation With Hetero
PremiumCompany Announcements
Catalyst Pharma Settles Firdapse Patent Litigation With Hetero
28d ago
8K
CPRX
Catalyst Pharmaceuticals downgraded to Equal Weight from Overweight at Stephens
PremiumThe Fly
Catalyst Pharmaceuticals downgraded to Equal Weight from Overweight at Stephens
28d ago
CPRX
Catalyst Pharmaceuticals to be acquired by Angelini Pharma for $31.50 per share
PremiumThe Fly
Catalyst Pharmaceuticals to be acquired by Angelini Pharma for $31.50 per share
28d ago
BX
CPRX
Analyst Initiates Buy on Catalyst Pharma, Citing M&A Appeal, Rare Disease Growth and $35 Price Target Backed by Strong Balance Sheet
PremiumRatings
Analyst Initiates Buy on Catalyst Pharma, Citing M&A Appeal, Rare Disease Growth and $35 Price Target Backed by Strong Balance Sheet
1M ago
CPRX
Angelini exploring acquisition of Catalyst Pharmaceuticals, Bloomberg says
PremiumThe FlyAngelini exploring acquisition of Catalyst Pharmaceuticals, Bloomberg says
1M ago
CPRX
Catalyst Pharmaceuticals trading resumes
Premium
The Fly
Catalyst Pharmaceuticals trading resumes
1M ago
CPRX
Catalyst Pharmaceuticals trading halted, volatility trading pause
Premium
The Fly
Catalyst Pharmaceuticals trading halted, volatility trading pause
1M ago
CPRX
Catalyst Pharma Patent Trial Against Hetero USA Delayed
PremiumCompany Announcements
Catalyst Pharma Patent Trial Against Hetero USA Delayed
3M ago
8K
CPRX
Catalyst Pharmaceutical Partners Signals Confident Growth Path
PremiumCompany Announcements
Catalyst Pharmaceutical Partners Signals Confident Growth Path
3M ago
CPRX
Buy Rating on Catalyst Pharma Driven by Strong 2026 Growth Outlook and Favorable Firdapse Litigation Upside
PremiumRatings
Buy Rating on Catalyst Pharma Driven by Strong 2026 Growth Outlook and Favorable Firdapse Litigation Upside
3M ago
CPRX
Catalyst Pharmaceuticals price target raised to $35 from $33 at Citi
PremiumThe Fly
Catalyst Pharmaceuticals price target raised to $35 from $33 at Citi
3M ago
CPRX
Buy Rating on Catalyst Pharma Backed by Strong Growth, Underpenetrated LEMS Opportunity, and Rising Profitability Post-Royalty Roll-Off
PremiumRatingsBuy Rating on Catalyst Pharma Backed by Strong Growth, Underpenetrated LEMS Opportunity, and Rising Profitability Post-Royalty Roll-Off
3M ago
CPRX
Catalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook
Premium
Company Announcements
Catalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook
3M ago
8K
CPRX
Catalyst Pharmaceuticals reports Q4 EPS 68c, consensus 50c
Premium
The Fly
Catalyst Pharmaceuticals reports Q4 EPS 68c, consensus 50c
3M ago
CPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >